Probiotics in the Management of Vulvovaginal Candidosis

Vulvovaginal candidosis (VVC) represents a frequent and cumbersome vaginal infection. Recurrent and/or persistent infections remain common among a significant number of patients despite the use of antifungals. Probiotics offer a promising adjunctive or alternative therapeutic strategy to antifungals...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JOURNAL OF CLINICAL MEDICINE 2024-09, Vol.13 (17)
Hauptverfasser: Akinosoglou, Karolina, Schinas, Georgios, Polyzou, Eleni, Tsiakalos, Aristotelis, Donders, Gilbert G.G
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 17
container_start_page
container_title JOURNAL OF CLINICAL MEDICINE
container_volume 13
creator Akinosoglou, Karolina
Schinas, Georgios
Polyzou, Eleni
Tsiakalos, Aristotelis
Donders, Gilbert G.G
description Vulvovaginal candidosis (VVC) represents a frequent and cumbersome vaginal infection. Recurrent and/or persistent infections remain common among a significant number of patients despite the use of antifungals. Probiotics offer a promising adjunctive or alternative therapeutic strategy to antifungals in the management of VVC. We aimed to explore and thoroughly examine the various roles and potential applications of probiotics in VVC. A comprehensive literature search was conducted to identify relevant clinical trials and systematic reviews that examine the effectiveness of probiotics in the treatment and prevention of VVC and recurrent VVC (rVVC). Following the initial screening of 4563 articles, a total of 25 clinical studies and seven systematic reviews were finally included in this analysis. The studies reviewed provide a generally positive yet inconsistent view of the efficacy of probiotics in managing VVC, including clinical, mycological response, and prevention perspectives. Nonetheless, fluconazole remains more effective than probiotics in treating VVC, while the combination of the two seems to reduce recurrence and improve symptoms significantly. For prevention, probiotics seem to improve vaginal health and reduce symptoms, while safety and tolerability are consistently reported across the studies, affirming that probiotics represent a low-risk intervention. However, clear conclusions are difficult to establish since relative studies explore different clinical endpoints and follow-up times, variable populations are included, different probiotics are used, and diverse schedules and regimens are administered. We propose that future studies should study the benefit of probiotics in well-defined categories such as (1) treatment with acute probiotics instead of antifungals, (2) adjuvant probiotic therapy together or after antifungals, and (3) VVC recurrence prevention using probiotics.
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_20_500_12942_749547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20_500_12942_749547</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_20_500_12942_7495473</originalsourceid><addsrcrecordid>eNqVjLEKwjAURYMoWGr_IbNQSZOUtHNRXAQHcQ2xSWs0JuJLi5-vg4Oj3uWc4XAnKKFEiJywik2_fI4ygAt5r6o4LUSCxP4RTjZE2wK2HsezwTvlVW9uxkccOnwc3BhG1VuvHG6U11YHsLBAs045MNmHKVpu1odmm18HZ4bReKnhrlojKZElIbKgNadS8LrkgqVo9XMs4zOyv95fC21I9w</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Probiotics in the Management of Vulvovaginal Candidosis</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Lirias (KU Leuven Association)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Akinosoglou, Karolina ; Schinas, Georgios ; Polyzou, Eleni ; Tsiakalos, Aristotelis ; Donders, Gilbert G.G</creator><creatorcontrib>Akinosoglou, Karolina ; Schinas, Georgios ; Polyzou, Eleni ; Tsiakalos, Aristotelis ; Donders, Gilbert G.G</creatorcontrib><description>Vulvovaginal candidosis (VVC) represents a frequent and cumbersome vaginal infection. Recurrent and/or persistent infections remain common among a significant number of patients despite the use of antifungals. Probiotics offer a promising adjunctive or alternative therapeutic strategy to antifungals in the management of VVC. We aimed to explore and thoroughly examine the various roles and potential applications of probiotics in VVC. A comprehensive literature search was conducted to identify relevant clinical trials and systematic reviews that examine the effectiveness of probiotics in the treatment and prevention of VVC and recurrent VVC (rVVC). Following the initial screening of 4563 articles, a total of 25 clinical studies and seven systematic reviews were finally included in this analysis. The studies reviewed provide a generally positive yet inconsistent view of the efficacy of probiotics in managing VVC, including clinical, mycological response, and prevention perspectives. Nonetheless, fluconazole remains more effective than probiotics in treating VVC, while the combination of the two seems to reduce recurrence and improve symptoms significantly. For prevention, probiotics seem to improve vaginal health and reduce symptoms, while safety and tolerability are consistently reported across the studies, affirming that probiotics represent a low-risk intervention. However, clear conclusions are difficult to establish since relative studies explore different clinical endpoints and follow-up times, variable populations are included, different probiotics are used, and diverse schedules and regimens are administered. We propose that future studies should study the benefit of probiotics in well-defined categories such as (1) treatment with acute probiotics instead of antifungals, (2) adjuvant probiotic therapy together or after antifungals, and (3) VVC recurrence prevention using probiotics.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><language>eng</language><publisher>MDPI</publisher><ispartof>JOURNAL OF CLINICAL MEDICINE, 2024-09, Vol.13 (17)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,780,784,27860</link.rule.ids></links><search><creatorcontrib>Akinosoglou, Karolina</creatorcontrib><creatorcontrib>Schinas, Georgios</creatorcontrib><creatorcontrib>Polyzou, Eleni</creatorcontrib><creatorcontrib>Tsiakalos, Aristotelis</creatorcontrib><creatorcontrib>Donders, Gilbert G.G</creatorcontrib><title>Probiotics in the Management of Vulvovaginal Candidosis</title><title>JOURNAL OF CLINICAL MEDICINE</title><description>Vulvovaginal candidosis (VVC) represents a frequent and cumbersome vaginal infection. Recurrent and/or persistent infections remain common among a significant number of patients despite the use of antifungals. Probiotics offer a promising adjunctive or alternative therapeutic strategy to antifungals in the management of VVC. We aimed to explore and thoroughly examine the various roles and potential applications of probiotics in VVC. A comprehensive literature search was conducted to identify relevant clinical trials and systematic reviews that examine the effectiveness of probiotics in the treatment and prevention of VVC and recurrent VVC (rVVC). Following the initial screening of 4563 articles, a total of 25 clinical studies and seven systematic reviews were finally included in this analysis. The studies reviewed provide a generally positive yet inconsistent view of the efficacy of probiotics in managing VVC, including clinical, mycological response, and prevention perspectives. Nonetheless, fluconazole remains more effective than probiotics in treating VVC, while the combination of the two seems to reduce recurrence and improve symptoms significantly. For prevention, probiotics seem to improve vaginal health and reduce symptoms, while safety and tolerability are consistently reported across the studies, affirming that probiotics represent a low-risk intervention. However, clear conclusions are difficult to establish since relative studies explore different clinical endpoints and follow-up times, variable populations are included, different probiotics are used, and diverse schedules and regimens are administered. We propose that future studies should study the benefit of probiotics in well-defined categories such as (1) treatment with acute probiotics instead of antifungals, (2) adjuvant probiotic therapy together or after antifungals, and (3) VVC recurrence prevention using probiotics.</description><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVjLEKwjAURYMoWGr_IbNQSZOUtHNRXAQHcQ2xSWs0JuJLi5-vg4Oj3uWc4XAnKKFEiJywik2_fI4ygAt5r6o4LUSCxP4RTjZE2wK2HsezwTvlVW9uxkccOnwc3BhG1VuvHG6U11YHsLBAs045MNmHKVpu1odmm18HZ4bReKnhrlojKZElIbKgNadS8LrkgqVo9XMs4zOyv95fC21I9w</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Akinosoglou, Karolina</creator><creator>Schinas, Georgios</creator><creator>Polyzou, Eleni</creator><creator>Tsiakalos, Aristotelis</creator><creator>Donders, Gilbert G.G</creator><general>MDPI</general><scope>FZOIL</scope></search><sort><creationdate>202409</creationdate><title>Probiotics in the Management of Vulvovaginal Candidosis</title><author>Akinosoglou, Karolina ; Schinas, Georgios ; Polyzou, Eleni ; Tsiakalos, Aristotelis ; Donders, Gilbert G.G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_20_500_12942_7495473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akinosoglou, Karolina</creatorcontrib><creatorcontrib>Schinas, Georgios</creatorcontrib><creatorcontrib>Polyzou, Eleni</creatorcontrib><creatorcontrib>Tsiakalos, Aristotelis</creatorcontrib><creatorcontrib>Donders, Gilbert G.G</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>JOURNAL OF CLINICAL MEDICINE</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akinosoglou, Karolina</au><au>Schinas, Georgios</au><au>Polyzou, Eleni</au><au>Tsiakalos, Aristotelis</au><au>Donders, Gilbert G.G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Probiotics in the Management of Vulvovaginal Candidosis</atitle><jtitle>JOURNAL OF CLINICAL MEDICINE</jtitle><date>2024-09</date><risdate>2024</risdate><volume>13</volume><issue>17</issue><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Vulvovaginal candidosis (VVC) represents a frequent and cumbersome vaginal infection. Recurrent and/or persistent infections remain common among a significant number of patients despite the use of antifungals. Probiotics offer a promising adjunctive or alternative therapeutic strategy to antifungals in the management of VVC. We aimed to explore and thoroughly examine the various roles and potential applications of probiotics in VVC. A comprehensive literature search was conducted to identify relevant clinical trials and systematic reviews that examine the effectiveness of probiotics in the treatment and prevention of VVC and recurrent VVC (rVVC). Following the initial screening of 4563 articles, a total of 25 clinical studies and seven systematic reviews were finally included in this analysis. The studies reviewed provide a generally positive yet inconsistent view of the efficacy of probiotics in managing VVC, including clinical, mycological response, and prevention perspectives. Nonetheless, fluconazole remains more effective than probiotics in treating VVC, while the combination of the two seems to reduce recurrence and improve symptoms significantly. For prevention, probiotics seem to improve vaginal health and reduce symptoms, while safety and tolerability are consistently reported across the studies, affirming that probiotics represent a low-risk intervention. However, clear conclusions are difficult to establish since relative studies explore different clinical endpoints and follow-up times, variable populations are included, different probiotics are used, and diverse schedules and regimens are administered. We propose that future studies should study the benefit of probiotics in well-defined categories such as (1) treatment with acute probiotics instead of antifungals, (2) adjuvant probiotic therapy together or after antifungals, and (3) VVC recurrence prevention using probiotics.</abstract><pub>MDPI</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof JOURNAL OF CLINICAL MEDICINE, 2024-09, Vol.13 (17)
issn 2077-0383
2077-0383
language eng
recordid cdi_kuleuven_dspace_20_500_12942_749547
source MDPI - Multidisciplinary Digital Publishing Institute; Lirias (KU Leuven Association); EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
title Probiotics in the Management of Vulvovaginal Candidosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A16%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Probiotics%20in%20the%20Management%20of%20Vulvovaginal%20Candidosis&rft.jtitle=JOURNAL%20OF%20CLINICAL%20MEDICINE&rft.au=Akinosoglou,%20Karolina&rft.date=2024-09&rft.volume=13&rft.issue=17&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E20_500_12942_749547%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true